Supplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Authors:
- Séverine GuiuSGSéverine Guiu
- Judith BalmañaJBJudith Balmaña
- Pablo LemercierPLPablo Lemercier
- Philippe FollanaPFPhilippe Follana
- Anthony GonçalvesAnthony Gonçalves
- Frédéric BigotFBFrédéric Bigot
- Jean-Sébastien FrenelJFJean-Sébastien Frenel
- Etienne BrainEBEtienne Brain
- Audrey MailliezAMAudrey Mailliez
- Camille Chakiba BrugereCBCamille Chakiba Brugere
- Elsa CurtitECElsa Curtit
- Olfa DerbelODOlfa Derbel
Open Access
- 14 November 2025
- other
- Published by American Association for Cancer Research (AACR)